SG11201808119UA - Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody - Google Patents
Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibodyInfo
- Publication number
- SG11201808119UA SG11201808119UA SG11201808119UA SG11201808119UA SG11201808119UA SG 11201808119U A SG11201808119U A SG 11201808119UA SG 11201808119U A SG11201808119U A SG 11201808119UA SG 11201808119U A SG11201808119U A SG 11201808119UA SG 11201808119U A SG11201808119U A SG 11201808119UA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- fragment
- ngf antibody
- human ngf
- pegylated fab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016061353 | 2016-03-25 | ||
PCT/JP2017/011910 WO2017164349A1 (fr) | 2016-03-25 | 2017-03-24 | Composition médicinale contenant un fragment fab' d'anticorps anti-ngf humain peg |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808119UA true SG11201808119UA (en) | 2018-10-30 |
Family
ID=59900467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808119UA SG11201808119UA (en) | 2016-03-25 | 2017-03-24 | Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200299371A1 (fr) |
EP (1) | EP3434283A4 (fr) |
JP (2) | JPWO2017164349A1 (fr) |
KR (1) | KR20180123559A (fr) |
CN (1) | CN108883177A (fr) |
CA (1) | CA3018473A1 (fr) |
MX (1) | MX2018011675A (fr) |
PH (1) | PH12018501978A1 (fr) |
RU (1) | RU2018137495A (fr) |
SG (1) | SG11201808119UA (fr) |
TW (1) | TW201738269A (fr) |
WO (1) | WO2017164349A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
JP7374544B2 (ja) * | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277828B1 (en) | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
EP1532983A1 (fr) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Preparation d'immunoglobulines à stabilité élevée |
US20070184050A1 (en) * | 2003-12-25 | 2007-08-09 | Kirin Beer Kabushiki Kaisha | Stable water-based medicinal preparation containing antibody |
EP2129401B8 (fr) * | 2006-12-21 | 2020-01-15 | Amgen Inc. | Formulations tamponnées stables contenant des polypeptides |
MX2011003013A (es) | 2008-09-19 | 2011-04-11 | Pfizer | Formulacion liquida estable de anticuerpos. |
JP2013522313A (ja) * | 2010-03-17 | 2013-06-13 | アボツト・リサーチ・ベー・フエー | 抗神経成長因子(ngf)抗体組成物 |
RS56876B1 (sr) | 2011-08-11 | 2018-04-30 | Astellas Pharma Inc | Novo antitelo protiv humanog ngf |
JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトngf抗体 |
-
2017
- 2017-03-24 EP EP17770389.9A patent/EP3434283A4/fr not_active Ceased
- 2017-03-24 CA CA3018473A patent/CA3018473A1/fr not_active Abandoned
- 2017-03-24 SG SG11201808119UA patent/SG11201808119UA/en unknown
- 2017-03-24 WO PCT/JP2017/011910 patent/WO2017164349A1/fr active Application Filing
- 2017-03-24 MX MX2018011675A patent/MX2018011675A/es unknown
- 2017-03-24 RU RU2018137495A patent/RU2018137495A/ru unknown
- 2017-03-24 KR KR1020187030401A patent/KR20180123559A/ko not_active Application Discontinuation
- 2017-03-24 US US16/087,908 patent/US20200299371A1/en not_active Abandoned
- 2017-03-24 CN CN201780019929.0A patent/CN108883177A/zh active Pending
- 2017-03-24 JP JP2018507426A patent/JPWO2017164349A1/ja active Pending
- 2017-03-24 TW TW106109999A patent/TW201738269A/zh unknown
-
2018
- 2018-09-13 PH PH12018501978A patent/PH12018501978A1/en unknown
-
2021
- 2021-11-10 JP JP2021182945A patent/JP7215555B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2017164349A1 (ja) | 2019-02-07 |
EP3434283A4 (fr) | 2019-11-13 |
CN108883177A (zh) | 2018-11-23 |
RU2018137495A (ru) | 2020-04-27 |
KR20180123559A (ko) | 2018-11-16 |
JP7215555B2 (ja) | 2023-01-31 |
JP2022023223A (ja) | 2022-02-07 |
US20200299371A1 (en) | 2020-09-24 |
CA3018473A1 (fr) | 2017-09-28 |
TW201738269A (zh) | 2017-11-01 |
EP3434283A1 (fr) | 2019-01-30 |
RU2018137495A3 (fr) | 2020-05-25 |
WO2017164349A1 (fr) | 2017-09-28 |
PH12018501978A1 (en) | 2019-06-17 |
MX2018011675A (es) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009475A (es) | Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
MY185802A (en) | Antibody formulation | |
EP4233892A3 (fr) | Formulation stable anti-ifnar1 | |
WO2015183963A3 (fr) | Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations | |
MY159156A (en) | Antibody formulation | |
WO2014165607A3 (fr) | Formulations peptidiques cationiques aromatiques, compositions et procédés d'utilisation | |
WO2018067217A3 (fr) | Compositions comprenant des peptides courts dérivés de pedf et leurs utilisations | |
WO2012017324A3 (fr) | Composition pharmaceutique à combinaison et méthodes de traitement de maladies ou états associés à des maladies neurodégénératives | |
MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
MX2020005170A (es) | Formulaciones de proteinas de fusion vegfr-fc. | |
EA201691018A1 (ru) | Фармацевтическая композиция, содержащая смесь проферментов и ферментов | |
MX2016000964A (es) | Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio. | |
GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
SG11201805123XA (en) | Pharmaceutical composition comprising anti-human tslp receptor antibody | |
MX2016013575A (es) | Composicion para prevenir o tratar enfermedades del higado graso. | |
PH12014501985A1 (en) | Il-17 antibody formulation | |
MX2022013566A (es) | Anticuerpo. | |
MX2016004926A (es) | Formulaciones de tampon para la estabilidad de anticuerpo mejorada. | |
SG11201808119UA (en) | Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody | |
MX2021007047A (es) | Formulaciones de anticuerpos. | |
MX2019005309A (es) | Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. | |
MX2016010852A (es) | Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso. | |
WO2015100370A3 (fr) | Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes | |
WO2015183984A3 (fr) | Compositions thérapeutiques contenant un tocophérol et leurs utilisations | |
WO2019087133A8 (fr) | Procédé de traitement d'une tendinopathie à l'aide d'antagonistes d'interleukine-17 (il-17) |